Search
Publications Icon

Publications

Why do publications about LTFU Study results refer to the Childhood Cancer Survivor Study (CCSS)?

Long-Term Follow-Up Study (LTFU) is the name we use when communicating about the study with participants, while Childhood Cancer Survivor Study (CCSS) is the scientific name used by researchers and the medical community. “Long-Term Follow-Up Study” emphasizes what the study is about without disclosing that some participants may be survivors of childhood cancer, thus protecting their personal health information.

You may hear about the Childhood Cancer Survivor Study or CCSS when important new findings are reported in the news. We want you to take pride in the attention the study receives, because your dedication contributes to every advance we make in protecting the health of survivors.

We're sorry, it looks like there has been an error. Please try again soon.

  • Comparison of radiation dose reconstruction methods to investigate late adverse effects of radiotherapy for childhood cancer: a report from the Childhood Cancer Survivor Study.

    2020

    Citation: 193(2):95-106

    Author(s): Schonfeld SJ, Howell RM, Smith SA, Neglia JP, Turcotte LM, Arnold MA, Inskip PD, Oeffinger KC, Moskowitz CS, Henderson TO, Leisenring WM, Gibson TM, Berrington de González A, Sampson JN, Chanock SJ, Tucker MA, Bhatia S, Robison LL, Armstrong GT, Morton LM.

    Journal: Radiat Res

  • Consistent physical activity and future neurocognitive problems in adult survivors of childhood cancers: a report from the Childhood Cancer Survivor Study.

    2020

    Citation: 38(18):2014-2052

    Author(s): Barlow-Krelina E, Chen Y, Yasui Y, Till C, Gibson TM, Ness KK, Leisenring WM, Howell RM, Nathan PC, Oeffinger KC, Robison LL, Armstrong GT, Krull KR, Edelstein K.

    Journal: J Clin Oncol

  • Cost-effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group screening guidelines to prevent heart failure in survivors of childhood cancer.

    2020

    Citation: 38(33):3851-3862

    Author(s): Ehrhardt MJ, Ward ZJ, Liu Q, Chaudhry A, Nohria A, Border W, Fulbright JM, Mulrooney DA, Oeffinger KC, Nathan PC, Leisenring WM, Constine LS, Gibson TM, Chow EJ, Howell RM, Robison LL, Armstrong GT, Hudson MM, Diller L, Yasui Y, Armenian SH, Yeh JM

    Journal: J Clin Oncol

  • Development and validation of an age-scalable cardiac model with substructures for dosimetry in late-effects studies of childhood cancer survivors. 

    2020

    Citation: 153:163-171

    Author(s): Shrestha S, Gupta AC, Bates JE, Lee C, Owens CA, Hoppe BS, Constine LS, Smith SA, Qiao Y, Weathers RE, Yasui Y, Court LE, Paulino AC, Pinnix CC, Kry SF, Followill DS, Armstrong GT, Howell RM.

    Journal: Radiother Oncol

  • Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma.

    2020

    Citation: 6(5):724-734

    Author(s): Mirabello L, Zhu B, Koster R, Karlins E, Dean M, Yeager M, Gianferante M, Spector L, Morton L, Karyadi D, Robison LL, Armstrong GT, Bhatia S, Song L, Pankratz N, Pinheiro M, Gastier-Foster JM, Gorlick R, de Toledo SRC, Petrilli AS, Patiño-Garcia A, Lecanda F, Gutierrez-Jimeno M, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary AF, Kurucu N, Ilhan IE, Ballinger ML, Thomas DM, Barkauskas DA, Mejia-Baltodano G, Valverde P, Hicks BD, Zhu B, Wang M, Hutchinson AA, Tucker M, Sampson J, Landi MT, Freedman ND, Gapstur S, Carter B, Hoover RN, Chanock SJ, Savage SA.

    Journal: JAMA Oncol

Related Information